ARATANA THERAPEUTICS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD; shares in millions, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Net loss
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development
Stock-based compensation expense
Depreciation and amortization expense
Impairment of acquired intangible assets
Impairment of intangible assets
Gain on sale of marketable securities
Gain on deconsolidation of a variable interest entity
Non-cash interest expense
Creditor fees
Market value adjustments to inventories
Change in fair value of contingent consideration
Change in fair value of derivative instruments
(Gain) loss on disposition of property and equipment
Deferred tax benefit

Changes in operating assets and liabilities:
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other liabilities
Licensing and collaboration commitment
Deferred income

Net cash used in operating activities
Cash flows from investing activities
Milestone payments for intangible assets
Purchases of property and equipment, net
Proceeds from sales of marketable securities
Purchase of investments
Proceeds from maturities of investments
Cash contributed as investment in a noncontrolled entity
Purchase of derivative instruments
Purchase of in-process research and development
Change in restricted cash
Net cash provided by (used in) investing activities

Cash flows from financing activities
Proceeds from issuance of loans payable, net of discount
Repurchase of common stock
Payments for debt issuance costs
Payments on loans payable
Payment for loans payable final payment fee, termination fee and other fees
Cash paid for contingent consideration
Taxes paid for awards vested under equity incentive plans
Proceeds from stock option exercises
Proceeds from issuance of common stock, net of commissions and underwriter fees
Cash paid for promissory notes
Net cash provided by (used in) financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Effect of exchange rate on cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Supplemental disclosure of noncash investing and financing activities:
Non-cash exercise of warrant
Contingent consideration relating to Okapi Sciences NV acquisition
Okapi Sciences NV
Total contingent consideration relating to Okapi Sciences NV acquisition
Note payable related to Okapi Sciences NV acquisition
Okapi Sciences NV
Total note payable related to Okapi Sciences NV acquisition
Stock issuance costs included in accounts payable
Non-cash exercise of warrants

Comments